AU2001286237A1 - Oral preparations with favorable disintegration characteristics - Google Patents
Oral preparations with favorable disintegration characteristicsInfo
- Publication number
- AU2001286237A1 AU2001286237A1 AU2001286237A AU8623701A AU2001286237A1 AU 2001286237 A1 AU2001286237 A1 AU 2001286237A1 AU 2001286237 A AU2001286237 A AU 2001286237A AU 8623701 A AU8623701 A AU 8623701A AU 2001286237 A1 AU2001286237 A1 AU 2001286237A1
- Authority
- AU
- Australia
- Prior art keywords
- water
- carmellose
- sodium
- disintegrant
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000002349 favourable effect Effects 0.000 title 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 2
- 229950008138 carmellose Drugs 0.000 abstract 2
- 239000007884 disintegrant Substances 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- 239000002492 water-soluble polymer binding agent Substances 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229920002261 Corn starch Polymers 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 229940099112 cornstarch Drugs 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000288234 | 2000-09-22 | ||
| JP2000-288234 | 2000-09-22 | ||
| PCT/JP2001/007983 WO2002024166A1 (fr) | 2000-09-22 | 2001-09-14 | Preparations orales dotees de bonnes caracteristiques de desagregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001286237A1 true AU2001286237A1 (en) | 2002-04-02 |
Family
ID=18771855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001286237A Abandoned AU2001286237A1 (en) | 2000-09-22 | 2001-09-14 | Oral preparations with favorable disintegration characteristics |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7727553B2 (ja) |
| EP (2) | EP1974724A3 (ja) |
| JP (1) | JP4868695B2 (ja) |
| AT (1) | ATE431136T1 (ja) |
| AU (1) | AU2001286237A1 (ja) |
| CA (2) | CA2424001C (ja) |
| DE (1) | DE60138722D1 (ja) |
| DK (1) | DK1327440T5 (ja) |
| ES (1) | ES2325764T3 (ja) |
| TW (2) | TWI289062B (ja) |
| WO (1) | WO2002024166A1 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2685780T3 (es) * | 2002-08-22 | 2018-10-11 | Sumitomo Dainippon Pharma Co., Ltd. | Agente para el tratamiento de esquizofrenia |
| SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
| CA2531980C (en) | 2003-06-23 | 2013-09-17 | Dainippon Sumitomo Pharma Co., Ltd. | Imide derivatives as therapeutic agents for senile dementia |
| US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
| CA2608690C (en) | 2005-05-18 | 2016-07-05 | Dainippon Sumitomo Pharma Co., Ltd. | Stable tablet containing droxidopa |
| BRPI0611409B8 (pt) | 2005-05-26 | 2021-05-25 | Dainippon Sumitomo Pharma Co | preparação oral compreendendo lurasidona |
| CN101198331B (zh) * | 2005-06-13 | 2012-05-02 | 大日本住友制药株式会社 | 增溶化制剂 |
| EP1923074A4 (en) * | 2005-08-10 | 2011-09-14 | Shionogi & Co | TABLET WHICH CAN BE ORALLY DISINTEGRATED |
| JPWO2007018190A1 (ja) * | 2005-08-10 | 2009-02-19 | 塩野義製薬株式会社 | 苦味抑制製剤 |
| WO2007077581A2 (en) * | 2006-01-02 | 2007-07-12 | Rubicon Research Private Limited | Pharmaceutical compositions |
| AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| US20090110716A1 (en) | 2007-10-31 | 2009-04-30 | Frank Bunick | Orally disintegrative dosage form |
| CN101945657B (zh) | 2008-02-11 | 2015-04-22 | 大日本住友制药株式会社 | 具有改善的溶出性的片剂 |
| WO2009151072A1 (ja) | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
| US20100209495A1 (en) * | 2008-09-17 | 2010-08-19 | Mylan Laboratories, Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
| US8784781B2 (en) | 2009-09-24 | 2014-07-22 | Mcneil-Ppc, Inc. | Manufacture of chewing gum product with radiofrequency |
| US20110318411A1 (en) | 2010-06-24 | 2011-12-29 | Luber Joseph R | Multi-layered orally disintegrating tablet and the manufacture thereof |
| US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
| WO2012107890A2 (en) * | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline forms of lurasidone hydrochloride |
| US9433620B2 (en) * | 2011-05-13 | 2016-09-06 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
| CN104321013B (zh) | 2012-03-21 | 2017-08-15 | 皇家飞利浦有限公司 | 用于基于ecg信号来提供睡眠质量的视觉表示的方法和装置 |
| US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
| US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
| US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
| JP6007169B2 (ja) * | 2012-11-30 | 2016-10-12 | 大原薬品工業株式会社 | アリピプラゾール無水物を含有する固形製剤の製造方法 |
| WO2014090386A1 (en) | 2012-12-11 | 2014-06-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
| JP6037824B2 (ja) * | 2012-12-28 | 2016-12-07 | ライオン株式会社 | エトドラク含有固形製剤 |
| JP2014129238A (ja) * | 2012-12-28 | 2014-07-10 | Lion Corp | エトドラク含有固形製剤 |
| RU2712267C2 (ru) | 2014-01-10 | 2020-01-28 | Джонсон энд Джонсон Консьюмер Инк. | Способ изготовления таблеток с использованием радиочастотного излучения и частиц с поглощающим покрытием |
| WO2016012898A1 (en) | 2014-07-25 | 2016-01-28 | Lupin Limited | Oral pharmaceutical composition of lurasidone |
| WO2016139683A2 (en) * | 2015-03-05 | 2016-09-09 | Jubilant Generics Limited | Pharmaceutical compositions of lurasidone and process for preparing the same |
| US10966928B2 (en) | 2016-03-25 | 2021-04-06 | Universiteit Gent | Oral dosage form |
| EP3432865B1 (en) | 2016-03-25 | 2021-05-19 | Universiteit Gent | Oral dosage form |
| CN109152787A (zh) * | 2016-03-31 | 2019-01-04 | 英特塞普特医药品公司 | 具有优越的溶出性的口服制剂 |
| WO2018043613A1 (ja) * | 2016-08-31 | 2018-03-08 | 大日本住友製薬株式会社 | 水性懸濁型製剤 |
| CA3048968A1 (en) | 2017-01-11 | 2018-07-19 | Piramal Enterprises Limited | Oral pharmaceutical composition of lurasidone and preparation thereof |
| US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| AT17300U3 (de) * | 2020-12-03 | 2022-02-15 | G L Pharma Gmbh | Feste orale pharmazeutische Zusammensetzung |
| JP2024538883A (ja) * | 2021-11-04 | 2024-10-24 | 上海雲晟研新生物科技有限公司 | ルラシドン塩酸塩口腔内崩壊フィルム組成物、その製造方法及び応用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61148114A (ja) | 1984-11-15 | 1986-07-05 | Teijin Ltd | ニフエジピンの顆粒剤 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| JPH04305526A (ja) * | 1991-03-28 | 1992-10-28 | Morishita Roussel Kk | 薬剤組成物 |
| ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
| US5811120A (en) | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
| US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| EP0839526A3 (en) * | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with fast buccal disintegration or dissolution |
| TW482675B (en) * | 1997-01-31 | 2002-04-11 | Green Cross Corp | Compositions for oral administration containing pyridazinone compounds technical field of the invention |
| CA2315088A1 (en) * | 1997-12-19 | 1999-07-01 | Smithkline Beecham Corporation | Process for manufacturing bite-dispersion tablets |
| US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
| JP4438121B2 (ja) * | 1998-04-27 | 2010-03-24 | 大正製薬株式会社 | 口腔内速崩錠及びその製造方法 |
| KR100267576B1 (ko) * | 1998-07-25 | 2000-11-01 | 허계성 | 활성성분을 분리함유한 츄잉 연질정제 및 그의 제조방법 |
| JP2000086503A (ja) | 1998-09-07 | 2000-03-28 | Pola Chem Ind Inc | 錠剤医薬組成物 |
| JP2000086509A (ja) | 1998-09-14 | 2000-03-28 | Taisho Yakuhin Kogyo Kk | ソファルコン含有製剤の製造方法 |
| US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
-
2001
- 2001-09-14 JP JP2002528202A patent/JP4868695B2/ja not_active Expired - Fee Related
- 2001-09-14 CA CA2424001A patent/CA2424001C/en not_active Expired - Lifetime
- 2001-09-14 AU AU2001286237A patent/AU2001286237A1/en not_active Abandoned
- 2001-09-14 AT AT01965637T patent/ATE431136T1/de not_active IP Right Cessation
- 2001-09-14 EP EP08156778A patent/EP1974724A3/en not_active Withdrawn
- 2001-09-14 WO PCT/JP2001/007983 patent/WO2002024166A1/ja not_active Ceased
- 2001-09-14 DK DK01965637T patent/DK1327440T5/da active
- 2001-09-14 CA CA2824077A patent/CA2824077C/en not_active Expired - Lifetime
- 2001-09-14 EP EP01965637A patent/EP1327440B1/en not_active Expired - Lifetime
- 2001-09-14 ES ES01965637T patent/ES2325764T3/es not_active Expired - Lifetime
- 2001-09-14 US US10/381,036 patent/US7727553B2/en not_active Expired - Lifetime
- 2001-09-14 DE DE60138722T patent/DE60138722D1/de not_active Expired - Lifetime
- 2001-09-19 TW TW090123036A patent/TWI289062B/zh not_active IP Right Cessation
- 2001-09-19 TW TW094103731A patent/TWI289063B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2002024166A1 (ja) | 2004-01-29 |
| ATE431136T1 (de) | 2009-05-15 |
| CA2424001C (en) | 2013-10-22 |
| CA2424001A1 (en) | 2003-03-20 |
| WO2002024166A1 (fr) | 2002-03-28 |
| ES2325764T3 (es) | 2009-09-16 |
| DE60138722D1 (de) | 2009-06-25 |
| EP1974724A2 (en) | 2008-10-01 |
| TWI289062B (en) | 2007-11-01 |
| CA2824077C (en) | 2016-01-26 |
| TWI289063B (en) | 2007-11-01 |
| DK1327440T3 (da) | 2009-06-08 |
| US20040028741A1 (en) | 2004-02-12 |
| JP4868695B2 (ja) | 2012-02-01 |
| TW200524642A (en) | 2005-08-01 |
| EP1327440A4 (en) | 2006-02-01 |
| EP1327440A1 (en) | 2003-07-16 |
| DK1327440T5 (da) | 2009-09-07 |
| CA2824077A1 (en) | 2002-03-28 |
| EP1974724A3 (en) | 2008-11-12 |
| US7727553B2 (en) | 2010-06-01 |
| EP1327440B1 (en) | 2009-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001286237A1 (en) | Oral preparations with favorable disintegration characteristics | |
| EP1884242A4 (en) | PHARMACEUTICAL COMPOSITION | |
| HUP0004383A2 (hu) | Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény | |
| KR100882156B1 (ko) | 나테글리니드 함유 제제 | |
| CA2371940A1 (en) | Pregelatinized starch in a controlled release formulation | |
| BG106870A (en) | Glyburide composition | |
| IE894048L (en) | New therapeutically active compound and a process for its¹preparation | |
| ZA992951B (en) | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. | |
| DE69311395D1 (de) | Sphäroidische Arzneimittelformulierung | |
| EP1738756A3 (en) | Esmolol formulation | |
| RU96116411A (ru) | Быстро распадающаяся готовая препаративная форма трамадола или соли трамадола | |
| WO2003015779A3 (de) | Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol | |
| DE60233552D1 (de) | Fenofibrattabletten | |
| NO20060991L (no) | Feksofenadinsammensetning og fremgangsmate til fremstilling | |
| NZ236168A (en) | Stereochemically pure r- or s- piperazinealkanamides; pharmaceutical compositions, methods of treatment and preparation | |
| IS7208A (is) | Snöggbráðnandi lyfjagjafarform til inntöku um munn | |
| EP1545471A1 (en) | Storage stable tablets of fosinopril sodium | |
| TR200202557T1 (tr) | Esmolol formülasyonu | |
| CA2457982A1 (en) | Use of nefiracetam for treating neurodegeneration | |
| EP1645273A3 (en) | Novel use of (R)-(-)-2-(5-(-flourophenyl)-3-pyridylmethylaminoethyl|-chromane and its physiologically acceptable salts | |
| NO20033855D0 (no) | Fremgangsmåte ved fremstilling av farmasöytiske tabletter inneholdende paroxetinhydrokloridanhydrat | |
| CA2320627A1 (en) | Medicament for treatment of diastolic dysfunction | |
| AU1376200A (en) | New pharmaceutical composition and the process for its preparation | |
| WO2005034954A3 (en) | Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation | |
| RU98114489A (ru) | СОСТАВ ИНГИБИТОРА 5α-РЕДУКТАЗЫ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ИСПОЛЬЗОВАНИЕ |